JP2011520903A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520903A5
JP2011520903A5 JP2011509679A JP2011509679A JP2011520903A5 JP 2011520903 A5 JP2011520903 A5 JP 2011520903A5 JP 2011509679 A JP2011509679 A JP 2011509679A JP 2011509679 A JP2011509679 A JP 2011509679A JP 2011520903 A5 JP2011520903 A5 JP 2011520903A5
Authority
JP
Japan
Prior art keywords
compound
salt
cyano
salt according
cyclopenta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011509679A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520903A (ja
JP5603327B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/043875 external-priority patent/WO2009140448A1/en
Publication of JP2011520903A publication Critical patent/JP2011520903A/ja
Publication of JP2011520903A5 publication Critical patent/JP2011520903A5/ja
Application granted granted Critical
Publication of JP5603327B2 publication Critical patent/JP5603327B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011509679A 2008-05-16 2009-05-14 テトラヒドロシクロペンタ[b]インドールアンドロゲン受容体調節物質 Active JP5603327B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5372208P 2008-05-16 2008-05-16
US61/053,722 2008-05-16
PCT/US2009/043875 WO2009140448A1 (en) 2008-05-16 2009-05-14 Tetrahydrocyclopenta[b]indole androgen receptor modulators

Publications (3)

Publication Number Publication Date
JP2011520903A JP2011520903A (ja) 2011-07-21
JP2011520903A5 true JP2011520903A5 (https=) 2012-06-28
JP5603327B2 JP5603327B2 (ja) 2014-10-08

Family

ID=40847864

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011509679A Active JP5603327B2 (ja) 2008-05-16 2009-05-14 テトラヒドロシクロペンタ[b]インドールアンドロゲン受容体調節物質

Country Status (18)

Country Link
US (1) US8486943B2 (https=)
EP (1) EP2297100B1 (https=)
JP (1) JP5603327B2 (https=)
KR (1) KR101278788B1 (https=)
CN (1) CN102026974B (https=)
AU (1) AU2009246348B2 (https=)
BR (1) BRPI0912394A2 (https=)
CA (1) CA2724629C (https=)
CY (1) CY1113341T1 (https=)
DK (1) DK2297100T3 (https=)
EA (1) EA019713B1 (https=)
ES (1) ES2396612T3 (https=)
HR (1) HRP20120917T1 (https=)
MX (1) MX2010012436A (https=)
PL (1) PL2297100T3 (https=)
PT (1) PT2297100E (https=)
SI (1) SI2297100T1 (https=)
WO (1) WO2009140448A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA98777C2 (en) 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
CA2716320C (en) 2008-02-22 2014-01-28 Radius Health, Inc. Selective androgen receptor modulators
AU2011212813B2 (en) 2010-02-04 2014-10-23 Radius Health, Inc. Selective androgen receptor modulators
HUE030072T2 (en) 2010-05-12 2017-04-28 Radius Health Inc Therapeutic prescriptions
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
ES3055185T3 (en) 2014-03-28 2026-02-10 Univ Duke Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
MX389702B (es) 2016-06-22 2025-03-20 Ellipses Pharma Ltd Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
US20180185347A1 (en) * 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ,インコーポレイテッド Rad1901-2hclの多形性形態
MX2020013713A (es) 2018-07-04 2021-03-02 Radius Pharmaceuticals Inc Formas polimorficas de rad1901-2hcl.
EP3924328A1 (en) 2019-02-12 2021-12-22 Radius Pharmaceuticals, Inc. Processes and compounds
CN115023225A (zh) * 2020-01-27 2022-09-06 伊尔根制药有限公司 用于治疗肾病的四氢环戊[b]吲哚化合物
CN116761598A (zh) * 2020-07-06 2023-09-15 新月生物科学 Fabp4调节化合物的抗病毒用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988820A (en) * 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
GB8924392D0 (en) * 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
GB9008108D0 (en) * 1990-04-10 1990-06-06 Bayer Ag Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles
DE4027278A1 (de) * 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
DE4131346A1 (de) * 1991-09-20 1993-03-25 Bayer Ag Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US7160909B2 (en) 2001-08-09 2007-01-09 Eli Lilly And Company Cyclopenta[b]indole derivatives as sPLA2 inhibitors
DE10164564B4 (de) * 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
AU2003231509A1 (en) * 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
US20060074124A1 (en) * 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
BRPI0507657A (pt) 2004-03-03 2007-07-10 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
WO2006058088A2 (en) 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
JP2008530229A (ja) 2005-02-17 2008-08-07 ワイス シクロアルキル縮合インドール、ベンゾチオフェン、ベンゾフランおよびインデン誘導体
CA2612723A1 (en) * 2005-06-24 2007-01-04 Eli Lilly And Company Tetrahydrocarbazole derivatives useful as androgen receptor modulators
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
WO2008019825A1 (en) 2006-08-14 2008-02-21 Santhera Pharmaceuticals (Schweiz) Ag Use of tricyclic indole derivatives for the treatment of muscular diseases
UA98777C2 (en) * 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators

Similar Documents

Publication Publication Date Title
JP2011520903A5 (https=)
HRP20120917T1 (hr) TETRAHIDROCIKLOPENTA[b]INDOLSKI MODULATORI ANDROGENOG RECEPTORA
JP2006182786A5 (https=)
JP2012532874A5 (https=)
JP2016534063A5 (https=)
JP2009535352A5 (https=)
JP2006143751A5 (https=)
JP2010077141A5 (https=)
JP2007535496A5 (https=)
JP2010518122A5 (https=)
JP2013545785A5 (https=)
JP2013518107A5 (https=)
JP2011528713A5 (https=)
GB2465897A (en) Respiratory disease treatment
JP2009533356A5 (https=)
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
JP2016522254A5 (https=)
JP2015522018A5 (https=)
JP2009523760A5 (https=)
JP2019515908A5 (https=)
JP2008539267A5 (https=)
JP2008539268A5 (https=)
JP2014505107A5 (https=)
JP2013514980A5 (https=)
JP2017501140A5 (https=)